ReviewEULAR rheumatology open2025
Management of systemic lupus erythematosus with kidney involvement: systematic literature review to inform the 2025 update of EULAR recommendations.
Review in EULAR rheumatology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk of chronic kidney disease in newly diagnosed SLE with preserved renal function: a national study.Rheumatology (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To identify, appraise, and synthesise current evidence regarding the management of systemic lupus erythematosus (SLE) with kidney involvement towards informing the 2025 update of the European Alliance of Associations for Rheumatology (EULAR) recommendations. Methods: The Task Force formulated 11 research questions grouped into 6 distinct sections, namely indications of diagnostic kidney biopsy; treatment targets; efficacy and safety of immune treatments in lupus nephritis (LN); efficacy and safety of nonimmune treatments; treatment duration; and indications for repeat kidney biopsy. A dedicated systematic literature review (SLR) was performed for each section. SLRs were performed in PubMed, Embase, and the Cochrane Central Register of Controlled Trials from January 2019 to March 2024. Results: Patients with SLE with low-grade proteinuria (<500-1000 mg/d) and/or haematuria may have histologically active disease, based on evidence of moderate quality. Observational studies of good quality have demonstrated an association between complete or partial renal response within the first 6 to 12 months and long-term kidney survival. A combination of 2 immunosuppressive agents, such as belimumab with mycophenolate mofetil (MMF)/cyclophosphamide, voclosporin with MMF, or obinutuzumab with MMF, is associated with higher response rates, based on high-quality randomised controlled trials (RCTs). Discontinuation of treatment has been linked with an increased risk of relapse, as evidenced by 3 RCTs with substantial heterogeneity. Conclusions: High-quality RCTs indicate a benefit from combination treatments compared with previous standard-of-care in LN. Patients who respond within the first year of treatment tend to have better long-term outcomes. Kidney biopsy is essential for diagnosis, but the role of repeat biopsy awaits confirmation from higher-quality studies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.